Does the media refer more to INDV or AMPH?

In the previous week, Indivior and Indivior both had 2 articles in the media. Indivior's average media sentiment score of 1.26 beat Amphastar Pharmaceuticals' score of 0.33 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OGN or AMPH?

In the previous week, Organon & Co. and Organon & Co. both had 2 articles in the media. Amphastar Pharmaceuticals' average media sentiment score of 0.33 beat Organon & Co.'s score of 0.32 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, AMPH or RGC?

Amphastar Pharmaceuticals has higher revenue and earnings than Regencell Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amphastar Pharmaceuticals $730.02M 1.50 $98.09M $1.69 15.27 Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media prefer AMPH or RGC?

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 2 articles in the media. Regencell Bioscience's average media sentiment score of 0.69 beat Amphastar Pharmaceuticals' score of 0.33 indicating that Regencell Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Amphastar Pharmaceuticals (AMPH) Competitors

$26.62 +0.81 (+3.14%)

Closing price 04:00 PM Eastern

Extended Trading

$26.64 +0.02 (+0.06%)

As of 04:38 PM Eastern

Compare

AMPH vs. INDV, OGN, TARS, ARQT, and RGC

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? Amphastar Pharmaceuticals's main competitors and comparable companies include Indivior (INDV), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), and Regencell Bioscience (RGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amphastar Pharmaceuticals compare to Indivior?

Indivior (NASDAQ:INDV) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Indivior has higher revenue and earnings than Amphastar Pharmaceuticals. Indivior is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.38	$210M	$2.79	12.71
Amphastar Pharmaceuticals	$730.02M	1.50	$98.09M	$1.69	15.27

Indivior has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Indivior presently has a consensus price target of $45.17, indicating a potential upside of 27.41%. Amphastar Pharmaceuticals has a consensus price target of $22.50, indicating a potential downside of 12.82%. Given Indivior's stronger consensus rating and higher possible upside, equities research analysts plainly believe Indivior is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Indivior and Indivior both had 2 articles in the media. Indivior's average media sentiment score of 1.26 beat Amphastar Pharmaceuticals' score of 0.33 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.3% of Indivior shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Indivior has a net margin of 26.65% compared to Amphastar Pharmaceuticals' net margin of 10.76%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Summary

Indivior beats Amphastar Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Organon & Co. and Organon & Co. both had 2 articles in the media. Amphastar Pharmaceuticals' average media sentiment score of 0.33 beat Organon & Co.'s score of 0.32 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organon & Co. has higher revenue and earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.89
Amphastar Pharmaceuticals	$730.02M	1.50	$98.09M	$1.69	15.27

Organon & Co. has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Organon & Co. currently has a consensus price target of $11.40, indicating a potential downside of 17.25%. Amphastar Pharmaceuticals has a consensus price target of $22.50, indicating a potential downside of 12.82%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Amphastar Pharmaceuticals beats Organon & Co. on 8 of the 14 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 2 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.33 beat Tarsus Pharmaceuticals' score of 0.33 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Amphastar Pharmaceuticals has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.02	-$66.42M	-$1.09	N/A
Amphastar Pharmaceuticals	$730.02M	1.50	$98.09M	$1.69	15.27

Tarsus Pharmaceuticals presently has a consensus target price of $100.86, indicating a potential upside of 39.65%. Amphastar Pharmaceuticals has a consensus target price of $22.50, indicating a potential downside of 12.82%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Tarsus Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Amphastar Pharmaceuticals presently has a consensus price target of $22.50, suggesting a potential downside of 12.82%. Arcutis Biotherapeutics has a consensus price target of $36.00, suggesting a potential upside of 47.00%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Amphastar Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$730.02M	1.50	$98.09M	$1.69	15.27
Arcutis Biotherapeutics	$376.07M	8.19	-$16.14M	$0.21	116.62

In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 2 mentions for Amphastar Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Amphastar Pharmaceuticals' score of 0.33 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Amphastar Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Regencell Bioscience?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$730.02M	1.50	$98.09M	$1.69	15.27
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 2 articles in the media. Regencell Bioscience's average media sentiment score of 0.69 beat Amphastar Pharmaceuticals' score of 0.33 indicating that Regencell Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Amphastar Pharmaceuticals currently has a consensus target price of $22.50, indicating a potential downside of 12.82%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Amphastar Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Regencell Bioscience's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Regencell Bioscience	N/A	N/A	N/A

Summary

Amphastar Pharmaceuticals beats Regencell Bioscience on 9 of the 11 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.13B	$12.35B	$7.19B	$13.28B
Dividend Yield	N/A	2.65%	2.53%	16.36%
P/E Ratio	15.75	795.15	274.47	26.16
Price / Sales	1.55	835.72	585.00	81.25
Price / Cash	6.00	86.17	76.82	53.72
Price / Book	1.55	10.71	11.21	6.34
Net Income	$98.09M	$2.84B	$3.50B	$381.90M
7 Day Performance	4.68%	-0.96%	-0.83%	-1.36%
1 Month Performance	15.54%	-5.81%	-5.42%	-4.29%
1 Year Performance	6.61%	-5.29%	4.36%	-0.33%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	1.645 of 5 stars	$26.62 +3.1%	$22.50 -15.5%	-0.7%	$1.13B	$730.02M	15.75	1,976
INDV Indivior	4.3731 of 5 stars	$36.59 -0.8%	$45.17 +23.4%	+47.3%	$4.32B	$1.24B	13.11	838	Positive News
OGN Organon & Co.	1.1272 of 5 stars	$13.75 +0.1%	$11.40 -17.1%	+34.4%	$3.61B	$6.22B	17.85	10,000
TARS Tarsus Pharmaceuticals	3.3268 of 5 stars	$76.69 -0.2%	$100.86 +31.5%	+3.5%	$3.37B	$451.36M	N/A	50	Analyst Downgrade
ARQT Arcutis Biotherapeutics	4.2437 of 5 stars	$26.75 -2.1%	$35.57 +33.0%	+15.3%	$3.36B	$376.07M	127.39	354	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. INDV, OGN, TARS, ARQT, and RGC

How does Amphastar Pharmaceuticals compare to Indivior?

Summary

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Summary

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. INDV, OGN, TARS, ARQT, and RGC

How does Amphastar Pharmaceuticals compare to Indivior?

Which has preferable earnings & valuation, INDV or AMPH?

Which has more risk and volatility, INDV or AMPH?

Do analysts prefer INDV or AMPH?

Does the media refer more to INDV or AMPH?

Do insiders & institutionals hold more shares of INDV or AMPH?

Is INDV or AMPH more profitable?

Summary

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Does the media prefer OGN or AMPH?

Which has better earnings and valuation, OGN or AMPH?

Which has more volatility & risk, OGN or AMPH?

Is OGN or AMPH more profitable?

Do analysts rate OGN or AMPH?

Do institutionals & insiders hold more shares of OGN or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Do insiders and institutionals hold more shares of TARS or AMPH?

Does the media refer more to TARS or AMPH?

Is TARS or AMPH more profitable?

Which has higher earnings and valuation, TARS or AMPH?

Do analysts prefer TARS or AMPH?

Which has more volatility & risk, TARS or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Do analysts prefer AMPH or ARQT?

Which has stronger valuation & earnings, AMPH or ARQT?

Does the media refer more to AMPH or ARQT?

Which has more risk and volatility, AMPH or ARQT?

Is AMPH or ARQT more profitable?

Do institutionals & insiders hold more shares of AMPH or ARQT?

Summary

How does Amphastar Pharmaceuticals compare to Regencell Bioscience?

Do insiders & institutionals hold more shares of AMPH or RGC?

Which has preferable valuation and earnings, AMPH or RGC?

Does the media prefer AMPH or RGC?

Which has more volatility and risk, AMPH or RGC?

Do analysts prefer AMPH or RGC?

Is AMPH or RGC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools